• Series C (2/2025)
• Series B (7/2023)
Laplace Interventional is developing a novel transcatheter treatment for patients suffering from Tricuspid Regurgitation. The company has developed a prosthetic valve delivered through a minimally invasive procedure with a goal of offering an increase in life expectancy and improved quality of life to TR patients worldwide.
• Seed (6/2024)
Diatiro is transforming kidney transplantation with its groundbreaking Kidney Pod. This FDA Breakthrough-Designated device ensures kidneys remain optimally cold during transplants, significantly boosting the success rate and making previously unusable organs viable.
• Bridge (3/2024)
• Series A (9/2022)
Agitated Solutions is reimagining ultrasound contrast. Designed by a physician to improve workflow efficiency, the revolutionary Orbis™ microbubble generator delivers consistent, high-density bubbles with extended duration.
• Series A (11/2023)
• Post-Seed Bridge (7/2022)
Melodi Health's mission is to transform the field of reconstructive surgery for women and their surgeons. MELODI MATRIX™ is a development stage soft tissue device that elutes antibiotics and absorbs into the body quickly.
• Series A (5/2023)
Pleural Dynamics is developing best-in-class solutions for the management of chronic, recurrent fluid collections within the body. Founded in 2020, The Company has developed innovative devices for both recurrent pleural effusions and refractory ascites.
• Post-Seed Bridge (3/2023)
Dosentrx delivers the precision of inpatient medication management in an outpatient setting. Through unparalleled engagement, support, communication and supervision, Dosentrx is focused on unlocking the key to better patient care and better outcomes.
• Seed (12/2022)
VOCxi Health is a breath diagnostics company focused on accurate, non-invasive, real-time, mobile disease identification to enable early detection and make late-stage disease diagnoses a thing of the past.